Antidiabetic Pioglitazone Powder 99% Pioglitazone Powder Raw Powder Pioglitazone

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung-Pioglitazone
• Product Name: Pioglitazone Hydrochloride
• Name: Pioglitazone Hydrochloride Powder
• Appearance: White Powder
• Color: White
• Store: Cool and Dry
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anthelmintics
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 112529-15-4
• Mf: C19h21cln2o3s
• Boiling Point: 575.4c at 760 Mmhg
• Melting Point: 193-194
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Xi′an Shaanxi
• Production Capacity: 5000kg/Month

Product Description

Antidiabetic Pioglitazone powder 99% Pioglitazone Powder Raw Powder Pioglitazone 

Product Description

Product Details

Product Name	Pioglitazone Hydrochloride
Appearance	White Powder
CAS No.	112529-15-4
MF	C19H21ClN2O3S

Pioglitazone is a new orally active thiazolidinedione (TZD) launched in the US for the treatment of  dependent diabetes mellitus (NIDDM). It can be synthesized in 4 steps, the last one transforming an alphabromoester into thiazolidine. As with other representatives in this class, it potently activates the nuclear receptor peroxisome proliferator-activated receptor gamma which is believed to be involved in the regulation of  resistance and adipogenesis. In several obese and obese diabetic animal models, treatment with Pioglitazone resulted in reductions in plasma glucose and serum lipids. In clinical studies, Pioglitazone at a once daily oral dose of 15-45 mg, as monotherapy or in combination with non-TZDs , was shown to significantly improve glycemic control in type-2 diabetes and demonstrated a beneficial effect on  resistance and other clinically relevant parameters as plasma levels of triglycerides or HDL-cholesterol. Pioglitazone is reported to be safe and well tolerated and is said to have a lower occurrence of hepatic toxicity as well as a low probability for drug interaction.

Application&Function

Pioglitazone is used to lower blood glucose levels in type 2 diabetes either alone or in combination with a sulfonylurea, metformin. While pioglitazone does decrease blood sugar levels, the main study that looked at the medication found no difference in the main cardiovascular outcomes that were looked at. The secondary outcome of death from all causes, myocardial infarction, and stroke were lower.
Pioglitazone has been found to reduce all-cause mortality in type 2 diabetic patients compared to other therapies, with a 60% reduction in mortality in those exposed to pioglitazone, compared to those never exposed. Another study found an all-cause mortality hazard ratio of 0.33 for pioglitazone after adjusting for >40 covariates.

Specification